The role of interleukin-1 in wound biology. Part II: In vivo and human translational studies

Anesth Analg. 2010 Dec;111(6):1534-42. doi: 10.1213/ANE.0b013e3181f691eb. Epub 2010 Oct 1.

Abstract

Background: In the accompanying paper, we demonstrate that genetic variation within Nalp1 could contribute to interstrain differences in wound chemokine production through altering the amount of interleukin (IL)-1 produced. We further investigate the role of IL-1 in incisional wound biology and its effect on wound chemokine production in vivo and whether this mechanism could be active in human subjects.

Methods: A well-characterized murine model of incisional wounding was used to assess the in vivo role of IL-1 in wound biology. The amount of 7 different cytokines/chemokines produced within an experimentally induced skin incision on a mouse paw and the nociceptive response was analyzed in mice treated with an IL-1 inhibitor. We also investigated whether human IL-1β or IL-1α stimulated the production of chemokines by primary human keratinocytes in vitro, and whether there was a correlation between IL-1β and chemokine levels in 2 experimental human wound paradigms.

Results: Administration of an IL-1 receptor antagonist to mice decreased the nociceptive response to an incisional wound, and reduced the production of multiple inflammatory mediators, including keratinocyte-derived chemokine (KC) and macrophage inhibitory protein (MIP)-1α, within the wounds. IL-1α and IL-1β stimulated IL-8 and GRO-α (human homologues of murine keratinocyte-derived chemokine) production by primary human keratinocytes in vitro. IL-1β levels were highly correlated with IL-8 in human surgical wounds, and at cutaneous sites of human ultraviolet B-induced sunburn injury.

Conclusions: IL-1 plays a major role in regulating inflammatory mediator production in wounds through a novel mechanism; by stimulating the production of multiple cytokines and chemokines, it impacts clinically important aspects of wound biology. These data suggest that administration of an IL-1 receptor antagonist within the perioperative period could decrease postsurgical wound pain.

MeSH terms

  • Analgesics / pharmacology
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Cells, Cultured
  • Cesarean Section
  • Chemokine CCL3 / metabolism
  • Chemokine CXCL1 / metabolism
  • Chemokines / metabolism*
  • Dermatologic Surgical Procedures*
  • Disease Models, Animal
  • Female
  • Humans
  • Inflammation Mediators / metabolism*
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin-1 / metabolism*
  • Interleukin-1alpha / metabolism
  • Interleukin-1beta / metabolism
  • Interleukin-8 / metabolism
  • Keratinocytes / drug effects
  • Keratinocytes / immunology*
  • Keratinocytes / radiation effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Pain, Postoperative / immunology
  • Pain, Postoperative / prevention & control
  • Pregnancy
  • Randomized Controlled Trials as Topic
  • Skin / drug effects
  • Skin / immunology
  • Skin / radiation effects
  • Sunburn / immunology
  • Time Factors
  • Translational Research, Biomedical
  • Wound Healing* / drug effects

Substances

  • Analgesics
  • Anti-Inflammatory Agents
  • CXCL1 protein, human
  • Ccl3 protein, mouse
  • Chemokine CCL3
  • Chemokine CXCL1
  • Chemokines
  • Inflammation Mediators
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Interleukin-1alpha
  • Interleukin-1beta
  • Interleukin-8
  • keratinocyte-derived chemokines